| Metric | FY2022 | FY2021 |
|---|---|---|
| Net loss | -$38.7M-90.5% | -$20.3M |
| Shares issued for services | $332K-84.6% | $2.1M |
| Amortization of stock options and restricted stock units | $2.6M-7.7% | $2.9M |
| Impairment of goodwill | $33.5M | — |
| Impairment of IP R&D assets | $3.3M | — |
| Amortization of intangibles | $109K-0.9% | $110K |
| Bad debt expense - related parties | $300K | — |
| Gain on settlement of liabilities, net | -$927K | — |
| Loss on extinguishment of convertible note payable | $10K | — |
| Deferred tax liability | -$943K-3700.9% | -$25K |
| Offering costs allocated to warrant liabilities | $604K | — |
| Change in fair value of derivative liabilities | -$15.1M-423.8% | $4.7M |
| Change in fair value of accrued issuable equity | $9K | — |
| Prepaid expenses and other current assets | $1.0M+173.9% | -$1.4M |
| Accounts payable | $1.2M+122.0% | -$5.5M |
| Accounts payable – related parties | -$215K | — |
| Accrued expenses | $320K+126.4% | -$1.2M |
| Accrued expenses – related parties | $170K+138.9% | -$437K |
| Accrued issuable equity | -$53K | — |
| Total adjustments | $26.6M+2690.4% | $953K |
| Net Cash Used In Operating Activities | -$12.1M+37.4% | -$19.4M |
| Shares issued for cash, net of issuance costs | $26.7M | — |
| Offering costs in connection with 2021 sale of stock and warrants | -$2.1M | — |
| Offering costs in connection with July 2022 sale of common stock and common stock warrants | -$530K | — |
| Offering costs in connection with December 2022 sale of common stock and common stock warrants | -$485K | — |
| Proceeds from loans payable | $1.1M-34.4% | $1.6M |
| Repayment of convertible debt – related parties | -$10K | — |
| Repayment of loans payable, net of adjustments (Note 9) | -$1.6M-323.4% | -$376K |
| Repayment of loans payable – related parties | -$81K+81.2% | -$432K |
| Proceeds from sale of July 2022 common stock and common stock warrants | $6.5M | — |
| Proceeds from sale of December 2022 common stock and common stock warrants | $6.0M | — |
| Proceeds from exercise of July 2022 pre-funded warrants | $263 | — |
| Proceeds from exercise of December 2022 pre-funded warrants | $150 | — |
| Net Cash Provided By Financing Activities | $10.9M-57.2% | $25.4M |
| Effect of Exchange Rate Changes on Cash | -$419-100.6% | $75K |
| Net (Decrease) Increase In Cash | -$1.3M-120.5% | $6.1M |
| Cash - Beginning of Period | $8.2M+290.1% | $2.1M |
| Cash - End of Period | $7.0M-15.3% | $8.2M |
| Cash paid during the period for interest | $15K-57.4% | $35K |
| Common stock issued upon conversion of KBL debt | $1.9M | — |
| Common stock issued upon conversion of 180 debt | $432K | — |
| Common stock issued in connection with repayment of related party loans and convertible notes | $851K | — |
| Shares and warrants issued for Alpha Settlement | $1.0M | — |
| Exchange of common stock equivalents for common stock | $146 | — |
| Shares issued to settle accounts payable | $1.8M | — |
| Reclassification of accrued issuable equity | $43K | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.